Kamada Ltd. Logo

Kamada Ltd.

Develops specialty plasma-derived therapeutics for rare and serious conditions.

KMDA | TA

Overview

Corporate Details

ISIN(s):
IL0010941198
LEI:
Country:
Israel
Address:
2 Holzman St, Science Park, 7670402 Rehovot
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kamada Ltd. is a vertically integrated global biopharmaceutical company focused on specialty plasma-derived therapeutics. The company develops, produces, and markets a portfolio of pharmaceuticals for rare and serious conditions, utilizing a proprietary platform technology for the extraction and purification of proteins from human plasma. Its key therapeutic areas include Alpha-1 Antitrypsin Deficiency (AATD), rabies prophylaxis, and prevention of cytomegalovirus (CMV) in transplant recipients. Kamada maintains a diverse portfolio of marketed products and a robust development pipeline, supported by industry-leading manufacturing and protein separation capabilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-02 16:03
Foreign Filer Report
Kamada to Participate in Upcoming September Investor Conferences
English 135.5 KB
2025-09-02 16:03
Foreign Filer Report
Kamada to Participate in Upcoming September Investor Conferences
English 36.3 KB
2025-08-13 16:00
Foreign Filer Report
Second Quarter and First Half 2025 Financial Results
English 4.1 MB
2025-08-13 16:00
Foreign Filer Report
Second Quarter and First Half 2025 Financial Results
English 36.8 KB
2025-08-11 16:00
Foreign Filer Report
FDA Approval of its Plasma Collection Center in Houston, Texas
English 184.4 KB
2025-08-11 16:00
Report Publication Announcement
FDA Approval of its Plasma Collection Center in Houston, Texas
English 36.5 KB
2025-08-06 16:05
Foreign Filer Report
to Announce Second Quarter and First Half Ended June 30, 2025, Financial Result…
English 155.6 KB
2025-08-06 16:05
Foreign Filer Report
to Announce Second Quarter and First Half Ended June 30, 2025, Financial Result…
English 36.5 KB
2025-08-05 17:33
Regulatory News Service
Due to an error, trade halt was initiated in KAMADA's shares instead of CAMTEK'…
Hebrew (modern) 62.0 KB
2025-06-17 16:00
Foreign Filer Report
Kamada Confirms Continuous Global Business Operations and Products Availability…
English 134.2 KB
2025-06-17 16:00
Regulatory News Service
Kamada Confirms Continuous Global Business Operations and Products Availability…
English 36.6 KB
2025-05-14 16:00
Foreign Filer Report
Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year …
English 8.4 MB
2025-05-14 16:00
Earnings Release
Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year …
English 36.5 KB
2025-05-07 16:00
Foreign Filer Report
Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025
English 151.4 KB
2025-05-07 16:00
Report Publication Announcement
Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025
English 36.3 KB

Automate Your Workflow. Get a real-time feed of all Kamada Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Kamada Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.